MNMD - Mind Medicine (MindM...

Mind Medicine (MindMed) Inc.

MNMD

NASDAQ

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

6.65 USD

-0.05 (-0.752%)

Overview Profile Financial Statements Financial Ratios Chart Analysis News Corporate Actions DCF

Valuation Date:

Mar 20, 2025 4:00 PM

Share Price on Valuation Date

$6.65

Stock Beta

2.398

Shares Outstanding

75368360

FMP

Home Terms of Service Privacy Policy Blog Careers FAQs Contact Us

API

Documentation Pricing Formulas Market Indexes

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.